Destination LVAD Success Depends On Patient Selection Study Shows
This article was originally published in The Gray Sheet
Executive Summary
A July 31 study in the journal Circulation offers some, but not enough, helpful hints to defining the patient population that benefits most from long-term support with left-ventricular assist devices, according to the study's lead investigator
You may also be interested in...
Thoratec HeartMate II Continuous-Flow LVAD Poses “Acceptable” Risks
A new study of Thoratec's HeartMate II continuous-flow left-ventricular assist device supports the growing consensus that patient selection has a far greater influence than device selection on the mortality rate of LVAD patients
Thoratec HeartMate II Continuous-Flow LVAD Poses “Acceptable” Risks
A new study of Thoratec's HeartMate II continuous-flow left-ventricular assist device supports the growing consensus that patient selection has a far greater influence than device selection on the mortality rate of LVAD patients
INTERMACS Registry Will Light The Way To Earlier VAD Therapy – Editorial
The ongoing INTERMACS registry holds the key to expanding the usefulness of ventricular assist devices from just extending life to improving the quality of life, according to Lynne Warner Stevenson, cardiac surgeon at Brigham and Women's Hospital, Boston